GlassScriptPhysician profile
Alejandro Rivera Rodriguez
NPI 1821239393
$1,614.01
in general payments reported to CMS, 2019-2025
12 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $87.24 · 2021: $23.14 · 2022: $211 · 2023: $333 · 2024: $275 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $732.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $635.11 | 2019-2024 | Prolia, Evenity, Krystexxa |
| Abbvie INC. | $375.54 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $266.01 | 2019-2024 | |
| Glaxosmithkline, LLC. | $62.75 | 2023-2024 | Benlysta |
| Abiomed | $56.48 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $41.85 | 2022-2023 | Saphnelo |
| Pfizer INC. | $40.21 | 2019-2022 | |
| Ucb, INC. | $32.40 | 2019-2021 | |
| Horizon Therapeutics Plc | $31.09 | 2019 | |
| Mallinckrodt Enterprises LLC | $29.78 | 2019 | |
| Lilly USA, LLC | $28.20 | 2019 | |
| Hikma Pharmaceuticals USA | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Rivera Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.